Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Currie

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
United European Gastroenterology Journal|February 6, 2015
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-CMichael Camilleri, Anthony J Lembo, Bernard J Lavins, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2012
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationRobert W Busby, Marco M Kessler, Wilmin P Bartolini, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2015
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP EffluxBoris Tchernychev, Pei Ge, Marco M Kessler, et al.
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
Journal of Medicinal Chemistry|April 5, 2002
Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitorE Ann Hallinan, Sofya Tsymbalov, Clifford R Dorn, et al.
European Journal of Pharmacology|September 25, 2010
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transitRobert W Busby, Alexander P Bryant, Wilmin P Bartolini, et al.
Life Sciences|March 24, 2010
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractAlexander P Bryant, Robert W Busby, Wilmin P Bartolini, et al.
Journal of Gastroenterology and Hepatology|January 11, 2018
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regionsYunsheng Yang, Jingyuan Fang, Xiaozhong Guo, et al.
The American Journal of Gastroenterology|September 19, 2012
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyWilliam D Chey, Anthony J Lembo, Bernard J Lavins, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
United European Gastroenterology Journal|February 6, 2015
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-CMichael Camilleri, Anthony J Lembo, Bernard J Lavins, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2012
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationRobert W Busby, Marco M Kessler, Wilmin P Bartolini, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2015
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP EffluxBoris Tchernychev, Pei Ge, Marco M Kessler, et al.
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
Journal of Medicinal Chemistry|April 5, 2002
Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitorE Ann Hallinan, Sofya Tsymbalov, Clifford R Dorn, et al.
European Journal of Pharmacology|September 25, 2010
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transitRobert W Busby, Alexander P Bryant, Wilmin P Bartolini, et al.
Life Sciences|March 24, 2010
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractAlexander P Bryant, Robert W Busby, Wilmin P Bartolini, et al.
Journal of Gastroenterology and Hepatology|January 11, 2018
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regionsYunsheng Yang, Jingyuan Fang, Xiaozhong Guo, et al.
The American Journal of Gastroenterology|September 19, 2012
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyWilliam D Chey, Anthony J Lembo, Bernard J Lavins, et al.
Pageof 5